
NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 4/15/2024)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.



NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 4/15/2024)

Protocol Number	Phase	Protocol Title
		A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to
A041501	III	Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
		A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-
AALL1821	II	ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
		A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with
ACNS2021	II	Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and
AGCT1531	III	Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell
AGCT1532	III	Tumors
		A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly
ANHL1931	III	Diagnosed Primary Mediastinal B-Cell Lymphoma
		A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and
AHOD2131	III	Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with
AOST2031	III	Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy
AOST2032	11/111	for Newly Diagnosed Osteosarcoma
		A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with
		Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO
ARST2031	Ш	Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
		A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab
E4412	1/11	Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma